NOVAVAX INC Interest Payable, Current
NOVAVAX INC (NVAX) had Interest Payable, Current of $5.08 million as of 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2021-03-01
- 2020-12-31: Interest Payable, Current $5.08M.
- 2020-09-30: Interest Payable, Current $2.03M.
- 2020-06-30: Interest Payable, Current $5.08M.
- 2020-03-31: Interest Payable, Current $2.03M.
| Period end | Interest Payable, Current |
|---|---|
| 2020-12-31 | $5.08M 10-K · filed 2021-03-01 |
| 2020-09-30 | $2.03M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $5.08M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $2.03M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $5.08M 10-K · filed 2021-03-01 |
| 2019-09-30 | $2.03M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $5.08M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $2.03M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $5.08M 10-K · filed 2020-03-11 |
| 2018-09-30 | $2.03M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $5.08M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $2.03M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $5.08M 10-K · filed 2019-03-18 |
| 2017-09-30 | $2.03M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $5.08M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $2.03M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $5.08M 10-K · filed 2018-03-14 |
| 2016-09-30 | $2.03M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $5.15M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $2.10M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $0.00 10-K · filed 2017-02-27 |
| 2013-12-31 | $75.00K 10-K · filed 2014-03-12 |
| 2012-12-31 | $45.00K 10-K · filed 2014-03-12 |
| 2011-12-31 | $32.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |